210 related articles for article (PubMed ID: 25933700)
21. Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy.
Yoo KE; Kang RY; Lee JY; Lee YJ; Suh SY; Kim KS; Kim HS; Lee SH; Lee BK
Support Care Cancer; 2015 Jul; 23(7):1969-77. PubMed ID: 25500718
[TBL] [Abstract][Full Text] [Related]
22. [Effect of oral dexamethasone given 24 hours previously on docetaxel-induced edema: a retrospective study].
Kato A; Masuda N; Makihara K; Ueno H; Hirohata K; Yamauchi K; Yasojima H; Mizutani M; Yamamura J; Komori K
Gan To Kagaku Ryoho; 2014 Feb; 41(2):211-4. PubMed ID: 24743199
[TBL] [Abstract][Full Text] [Related]
23. [Clinical analysis of premedication regimen with dexamethasone at different doses for docetaxel-induced hypersensitivity reaction].
Zhang MJ; Chen ZD; Pan YY
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):795. PubMed ID: 20021838
[No Abstract] [Full Text] [Related]
24. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
[TBL] [Abstract][Full Text] [Related]
25. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
26. Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication.
Zhou JN; Huang XE; Ye Z; Li C; Zhang Q; Lin Y; Jiang W; Sunh WL; Shi MQ; Shu YQ
Asian Pac J Cancer Prev; 2009; 10(6):1147-50. PubMed ID: 20192601
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
28. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
[TBL] [Abstract][Full Text] [Related]
31. The patient-provider discordance in patients' needs assessment: a qualitative study in breast cancer patients receiving oral chemotherapy.
Wei C; Nengliang Y; Yan W; Qiong F; Yuan C
J Clin Nurs; 2017 Jan; 26(1-2):125-132. PubMed ID: 27647758
[TBL] [Abstract][Full Text] [Related]
32. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.
Baur M; van Oosterom AT; Diéras V; Tubiana-Hulin M; Coombes RC; Hatschek T; Murawsky M; Klink-Alakl M; Hudec M; Dittrich C
J Cancer Res Clin Oncol; 2008 Feb; 134(2):125-35. PubMed ID: 17636328
[TBL] [Abstract][Full Text] [Related]
34. Factors predicting docetaxel-related toxicity: experience at a single institution.
Massacesi C; Marcucci F; Rocchi MB; Mazzanti P; Pilone A; Bonsignori M
J Chemother; 2004 Feb; 16(1):86-93. PubMed ID: 15078005
[TBL] [Abstract][Full Text] [Related]
35. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Köppler H; Heymanns J; Weide R
Onkologie; 2001 Jun; 24(3):283-5. PubMed ID: 11455223
[TBL] [Abstract][Full Text] [Related]
36. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
Oncology; 2010; 79(3-4):197-203. PubMed ID: 21358207
[TBL] [Abstract][Full Text] [Related]
37. The role of taxanes in the treatment of breast cancer.
Capri G; Tarenzi E; Fulfaro F; Gianni L
Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Valero V
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PubMed ID: 9335512
[TBL] [Abstract][Full Text] [Related]
39. [Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer].
Kawabata H; Iwatani T; Makuuchi R; Miura D; Suzuki N; Nakazawa H
Gan To Kagaku Ryoho; 2010 May; 37(5):835-9. PubMed ID: 20495312
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Schmidinger M; Budinsky AC; Wenzel C; Locker GJ; Pluschnig U; Brodowicz T; Kubista E; Maca S; Zabernigg A; Ilsinger P; Seewann L; Hojas S; Blach M; Zielinski CC; Steger GG
Cancer Chemother Pharmacol; 2001; 47(1):57-62. PubMed ID: 11221963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
